Organization | Novavax

Novavax Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Gaithersburg MD United States (1999)

Organization Overview

First Clinical Trial

2007

NCT00519389

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Novavax | Novavax Inc | Novavax, Inc.

Active Ingredients

Drugs in Phase 4 Trials (2)

bnt162b2 (Comirnaty) (3 trials)

nvx-cov2373 (Covovax) (8 trials)

Drugs in Phase 3 Trials (8)

Key: Novavax (7) Acquired (1)

bbibp-corv (1 trial)

bivalent bnt162b2 (Comirnaty) (1 trial)

inactivated influenza vaccine (8 trials)

matrix m1 (13 trials)

nvx-cov2601 (2 trials)

phosphate (3 trials)

rsv-f subunit vaccine (10 trials)

sars-cov-2 rs (7 trials)

Drugs in Phase 2 Trials (12)

aluminum (1 trial)

b.1.351 (1 trial)

b.1.617.2 (1 trial)

influenza vlp vaccine (8 trials)

monoaluminum phosphate (1 trial)

nvx-cov2372 (1 trial)

qniv nanoparticle vaccine2 (2 trials)

rsv f vaccine (4 trials)

rsv sf (1 trial)

sii bivalent (1 trial)

sodium chloride (1 trial)

tivantinib (3 trials)

Drugs in Phase 1 Trials (5)

ebov gp vaccine (1 trial)

hepatitis a vaccine, inactivated (vaqta) (1 trial)

inactivated rabies vaccine (Imovax) (1 trial)

pfs230d1-epa/matrix-m vaccine (1 trial)

r0.6c transmission blocking vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Coronavirus Infections (Phase 3)

Hemorrhagic Fever, Ebola (Phase 1)

Influenza, Human (Phase 3)

Influenza in Birds (Phase 2)

Respiratory Syncytial Virus Infections (Phase 3)

Severe Acute Respiratory Syndrome (Phase 3)

Virus Diseases (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 47
# of Trial APIs: 27